Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free CLDX Stock Alerts

Celldex Therapeutics (CLDX) Short Interest Ratio & Short Volume

Celldex Therapeutics logo
$39.12 -1.34 (-3.31%)
As of 08/28/2026 04:00 PM Eastern
Compare

Celldex Therapeutics Short Interest Overview

As of August 14, 2026, Celldex Therapeutics (CLDX) had a short interest of 7.57 million shares sold short, representing 10.17% of the public float. This marks a -0.75% decrease in short interest since the prior report. The short interest ratio (days to cover) is 7.9, meaning it would take 7.9 days of the average trading volume of 868,254 shares to cover all short positions.

Current Short Interest
7,569,702 shares
Previous Short Interest
7,627,081 shares
Change Vs. Previous Month
-0.75%
Dollar Volume Sold Short
$317.55 million
Short Interest Ratio
7.9 Days to Cover
Last Record Date
August 14, 2026
Outstanding Shares
78,530,000 shares
Short Percent of Float
10.17%
Today's Trading Volume
424,938 shares
Average Trading Volume
868,254 shares
Today's Volume Vs. Average
49%
Short Selling Celldex Therapeutics?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Celldex Therapeutics and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

CLDX Short Interest Over Time

CLDX Days to Cover Over Time

CLDX Percentage of Float Shorted Over Time

Celldex Therapeutics Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
8/14/20267,569,702 shares $317.55 million -0.8%10.2%7.93 $41.95
7/31/20267,627,081 shares $290.29 million -0.5%10.3%7.62 $38.06
7/15/20267,663,191 shares $293.58 million -1.0%10.3%9.14 $38.31
6/30/20267,738,673 shares $287.96 million +6.1%10.4%4.3 $37.21
6/15/20267,295,393 shares $234.33 million +2.1%9.8%9.05 $32.12
5/29/20267,144,877 shares $224.56 million +0.2%9.6%10.73 $31.43
5/15/20267,130,776 shares $223.48 million -6.2%9.6%10.06 $31.34
4/30/20267,599,353 shares $249.87 million -8.5%10.2%9.41 $32.88
4/15/20268,309,099 shares $281.43 million -8.5%11.2%5.54 $33.87
3/31/20269,075,800 shares $287.88 million -1.8%12.2%8.49 $31.72
3/13/20269,237,012 shares $272.58 million +2.6%14.5%9.95 $29.51
2/27/20269,006,071 shares $270.99 million -1.9%12.1%8.44 $30.09
2/13/20269,181,713 shares $211.18 million -0.6%12.3%13.3 $23.00
1/30/20269,237,135 shares $227.23 million +2.2%14.5%19.42 $24.60
1/15/20269,034,401 shares $232.09 million +9.6%14.2%10.84 $25.69
12/31/20258,244,450 shares $223.92 million +20.1%13.0%12.26 $27.16
12/15/20256,865,432 shares $185.98 million -20.9%10.8%7.9 $27.09
11/28/20258,675,509 shares $234.20 million -1.9%13.7%13.27 $27.00
11/14/20258,845,278 shares $226.00 million +17.8%13.9%8.49 $25.55
10/31/20257,509,487 shares $200.73 million +1.5%11.8%10.41 $26.73
10/15/20257,400,000 shares $202.32 million +4.5%11.7%6.1 $27.34
9/30/20257,080,000 shares $183.16 million +7.6%N/A5.9 $25.87
9/15/20256,580,000 shares $161.21 million -8.7%N/A5.2 $24.50
8/31/20257,210,000 shares $159.20 million -1.4%11.4%5.7 $22.08
8/15/20257,310,000 shares $186.41 million -6.0%N/A6.1 $25.50
7/31/20257,780,000 shares $171.00 million -8.2%12.3%7.5 $21.98
7/15/20258,470,000 shares $193.54 million +7.6%N/A8.6 $22.85
6/30/20257,870,000 shares $160.15 million +0.5%12.4%7.9 $20.35
6/15/20257,830,000 shares $166.47 million -6.5%12.3%8.3 $21.26
5/31/20258,370,000 shares $163.13 million -8.3%13.1%9.6 $19.49
5/15/20259,130,000 shares $183.51 million +1.3%14.3%11.3 $20.10
4/30/20259,010,000 shares $187.68 million +2.6%N/A11.6 $20.83
4/15/20258,780,000 shares $161.29 million +5.8%13.8%11 $18.37
3/31/20258,300,000 shares $150.65 million -9.3%13.0%9.3 $18.15
3/15/20259,150,000 shares $186.84 million +3.0%14.3%10.5 $20.42
2/28/20258,880,000 shares $182.66 million -3.4%13.9%9.7 $20.57
2/15/20259,190,000 shares $208.61 million +3.6%14.4%9.8 $22.70
1/31/20258,870,000 shares $217.23 million +4.6%N/A8.8 $24.49
1/15/20258,480,000 shares $191.82 million +4.8%N/A8.2 $22.62
12/31/20248,090,000 shares $204.43 million +10.7%N/A8 $25.27
The REAL Reason Trump is Invading Iran (Ad)

For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.tc pixel

Click here to find out what it is.
12/15/20247,310,000 shares $185.75 million -5.1%N/A6 $25.41
11/30/20247,700,000 shares $211.29 million -1.7%N/A6.5 $27.44
11/15/20247,830,000 shares $184.40 million -5.0%N/A6.8 $23.55
10/31/20248,240,000 shares $214.73 million -1.9%N/A7.7 $26.06
10/15/20248,400,000 shares $246.96 million +1.1%N/A8.3 $29.40
9/30/20248,310,000 shares $282.46 million -1.2%N/A8.5 $33.99
9/15/20248,410,000 shares $371.39 million -1.9%N/A11.4 $44.16
8/31/20248,570,000 shares $354.20 million -1.0%N/A12.2 $41.33
8/15/20248,660,000 shares $286.65 million +3.1%N/A12.2 $33.10
7/31/20248,400,000 shares $320.12 million +13.7%N/A12.1 $38.11
7/15/20247,390,000 shares $292.27 million +5.7%N/A11.5 $39.55
6/30/20246,990,000 shares $258.70 million +8.7%N/A10.9 $37.01
6/15/20246,430,000 shares $222.93 million +2.6%N/A10.1 $34.67
5/31/20246,270,000 shares $208.79 million -5.3%N/A9.1 $33.30
5/15/20246,620,000 shares $265.93 million -5.3%N/A7.4 $40.17
4/30/20246,990,000 shares $261.57 million +3.6%N/A7.7 $37.42
4/15/20246,750,000 shares $263.72 million +2.9%N/A7.3 $39.07
3/31/20246,560,000 shares $275.32 million +11.2%N/A6.9 $41.97
3/15/20245,900,000 shares $247.86 million -8.0%N/A6.4 $42.01
2/29/20246,410,000 shares $308.06 million -7.6%N/A7.4 $48.06
2/15/20246,940,000 shares $255.39 million +3.4%N/A9.3 $36.80
1/31/20246,710,000 shares $236.33 million +7.9%N/A8.5 $35.22
1/15/20246,220,000 shares $261.49 million -5.6%N/A7.6 $42.04
12/31/20236,590,000 shares $261.36 million -10.3%N/A8.6 $39.66
12/15/20237,350,000 shares $273.05 million -8.9%N/A9.6 $37.15
11/30/20238,070,000 shares $243.79 million +2.4%N/A11.1 $30.21
11/15/20237,880,000 shares $224.82 million +40.2%N/A11.3 $28.53
10/31/20235,620,000 shares $132.18 million +0.9%N/A9.2 $23.52
10/15/20235,570,000 shares $145.60 million -3.3%N/A12.1 $26.14
9/30/20235,760,000 shares $158.52 million -5.4%N/A13.1 $27.52
9/15/20236,090,000 shares $170.22 million -3.3%N/A14.3 $27.95
8/31/20236,300,000 shares $175.77 million -3.7%N/A13.5 $27.90
8/15/20236,540,000 shares $205.55 million +8.5%N/A14.3 $31.43
7/31/20236,030,000 shares $213.22 million -3.8%N/A13.8 $35.36
7/15/20236,270,000 shares $233.81 million +1.8%N/A13.5 $37.29
6/30/20236,160,000 shares $209.01 million +2.7%N/A11 $33.93
6/15/20236,000,000 shares $221.22 million +3.5%N/A9.8 $36.87
5/31/20235,800,000 shares $184.44 million +7.0%N/A9.3 $31.80
5/15/20235,420,000 shares $185.69 million +1.1%N/A8.4 $34.26
4/30/20235,360,000 shares $168.52 million +3.5%N/A8.4 $31.44
4/15/20235,180,000 shares $156.90 million -1.7%N/A8.6 $30.29
3/31/20235,270,000 shares $189.61 million +38.0%N/A9.9 $35.98
3/15/20233,820,000 shares $167.13 million +5.5%N/A8 $43.75
2/28/20233,620,000 shares $154.90 million +4.3%N/A7.5 $42.79
2/15/20233,470,000 shares $148.79 million +4.5%N/A7.7 $42.88
1/31/20233,320,000 shares $146.28 million -4.3%N/A6.8 $44.06
1/15/20233,470,000 shares $159.69 million +1.8%N/A7 $46.02
12/30/20223,410,000 shares $151.98 million -17.2%N/A6.8 $44.57
12/15/20224,120,000 shares $182.47 million +1.7%N/A8 $44.29
11/30/20224,050,000 shares $150.21 million -1.9%N/A9 $37.09
Major Buy Alert Issued for August 31st (Ad)

Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 people worldwide. His system has flagged a handful of stocks worth watching ahead of August 31st. See which stocks his AI research platform is flagging right now.tc pixel

See which stocks his AI research platform is flagging now
11/15/20224,130,000 shares $151.53 million -8.2%N/A9 $36.69
10/31/20224,500,000 shares $158.09 million -0.9%N/A9.7 $35.13
10/15/20224,540,000 shares $142.74 million -1.5%N/A9.3 $31.44
9/30/20224,610,000 shares $129.59 million +2.4%N/A9 $28.11
9/15/20224,500,000 shares $136.40 million +2.3%N/A6.2 $30.31
8/31/20224,400,000 shares $133.76 million +4.0%N/A5.6 $30.40
8/15/20224,230,000 shares $158.92 million +14.3%N/A5.1 $37.57
7/31/20223,700,000 shares $113.66 million -2.9%30.7%4.3 $30.72
7/15/20223,810,000 shares $111.79 million -0.3%31.6%4.5 $29.34
6/30/20223,820,000 shares $102.99 million -18.9%31.7%4.7 $26.96
6/15/20224,710,000 shares $104.99 million +1.5%39.0%7.3 $22.29
5/31/20224,640,000 shares $109.13 million -5.5%N/A8 $23.52
5/15/20224,910,000 shares $147.25 million -1.0%N/A8.7 $29.99
4/30/20224,960,000 shares $151.53 million -9.3%N/A9 $30.55
4/15/20225,470,000 shares $196.04 million -0.2%N/A9.8 $35.84
3/31/20225,480,000 shares $186.65 million -8.7%N/A9.3 $34.06
3/15/20226,000,000 shares $187.26 million +3.3%N/A10.3 $31.21
2/28/20225,810,000 shares $173.72 million +11.7%N/A10 $29.90
2/15/20225,200,000 shares $169.78 million +2.4%N/A9.4 $32.65
1/31/20225,080,000 shares $157.53 million +3.3%N/A9.9 $31.01
1/15/20224,920,000 shares $157.00 million +3.1%N/A0 $31.91
12/31/20214,770,000 shares $184.31 million +9.9%N/A10.6 $38.64
12/15/20214,340,000 shares $166.92 million +6.6%N/A10.1 $38.46
11/30/20214,070,000 shares $155.07 million +12.4%N/A9.7 $38.10
11/15/20213,620,000 shares $155.70 million -2.7%N/A8.2 $43.01
10/29/20213,720,000 shares $158.25 million +25.7%N/A7.9 $42.54
10/15/20212,960,000 shares $136.69 million -0.7%N/A5.7 $46.18
9/30/20212,980,000 shares $160.89 million -11.0%N/A3.8 $53.99
9/15/20213,350,000 shares $178.25 million -15.4%N/A3.7 $53.21
8/31/20213,960,000 shares $208.49 million -8.1%N/A4.4 $52.65

CLDX Short Interest - Frequently Asked Questions

Short interest is the volume of Celldex Therapeutics shares that have been sold short but have not yet been covered or closed out. As of August 14th, investors have sold 7,569,702 shares of CLDX short. 10.17% of Celldex Therapeutics' shares are currently sold short. Learn More on Celldex Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CLDX shares currently have a short interest ratio of 7.9. Learn More on Celldex Therapeutics's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 10.17% of Celldex Therapeutics' floating shares are currently sold short.

Celldex Therapeutics saw a decline in short interest in the month of August. As of August 14th, there was short interest totaling 7,569,702 shares, a decline of 0.8% from the previous total of 7,627,081 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

10.17% of Celldex Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to Celldex Therapeutics: Exelixis, Inc. (11.61%), BioMarin Pharmaceutical Inc. (5.31%), Arrowhead Pharmaceuticals, Inc. (6.78%), Madrigal Pharmaceuticals, Inc. (10.64%), Halozyme Therapeutics, Inc. (13.23%), Abivax SA Sponsored ADR (6.88%), Praxis Precision Medicines, Inc. (13.72%), Protagonist Therapeutics, Inc. (12.70%), Summit Therapeutics PLC (28.44%), Kymera Therapeutics, Inc. (14.86%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($71.57 billion), Invesco QQQ ($46.97 billion), iShares Russell 2000 ETF ($24.02 billion), Nebius Group N.V. ($15.37 billion), Sandisk Corporation ($12.60 billion), SPDR S&P Biotech ETF ($12.14 billion), Western Digital Corporation ($10.32 billion), iShares 20+ Year Treasury Bond ETF ($8.38 billion), VanEck Semiconductor ETF ($7.62 billion), and iShares iBoxx $ High Yield Corporate Bond ETF ($7.07 billion). View all of the most shorted stocks.

Short selling CLDX is an investing strategy that aims to generate trading profit from Celldex Therapeutics as its price is falling. CLDX shares are trading down $1.34 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Celldex Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CLDX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CLDX, twice per month. The most recent reporting period available is August, 14 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like CLDX:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

Short interest data for NASDAQ:CLDX is sourced from the Financial Industry Regulatory Authority (FINRA), with the most recent report published on 8/25/2026. FINRA publishes updated short interest twice a month.
From Our Partners
MILLIONAIRE MASTERCLASS INVITE: Altucher
James Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...
Paradigm Press | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
In 1999, George Gilder predicted phones would outpower desktop computers. Apple's iPhone followed, and the sto...
Eagle Publishing | Sponsoredtc pixel
A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...
Awesomely | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
Leading AI Insider Issues Urgent Market Warning
A leading AI pioneer has spent $17 million on AI research and tools since 2022, building a platform now used b...
TradeSmith | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Buy this stock today
Most tech companies skip dividends entirely. This one doesn't, paying shareholders like clockwork while flying...
Chaikin Analytics | Sponsoredtc pixel
Hormuz tanker traffic collapses as the oil crisis deepens
Tanker traffic through Hormuz has plunged from 110-130 daily transits to near zero, while 17% of Qatar's LNG c...
Golden Portfolio | Sponsoredtc pixel